Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: A pilot study

Liver International

Volumn 34, Issue 1, 2014, Pages 33-41

  Jang, Yoon Ok ^a   Kim, Young Ju ^a   Baik, Soon Koo ^a   Kim, Moon Young ^a   Eom, Young Woo ^a   Cho, Mee Yon ^a   Park, Hong Jun ^a   Park, So Yeon ^a   Kim, Bo Ra ^a   Kim, Jae Woo ^a   Soo Kim, Hyun ^a   Kwon, Sang Ok ^a   Choi, Eun Hee ^a   Kim, Yong Man ^b  

^a Yonsei University Wonju College of Medicine   (South Korea)

^b FCB Pharmicell Co Ltd   (South Korea)

Author keywords

Bone marrow derived mesenchymal stem cell; Cirrhosis; Hepatic fibrosis; Liver function; Portal hypertension

Indexed keywords

5' NUCLEOTIDASE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD14 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; COLLAGEN TYPE 1; CREATININE; ENDOGLIN; GAMMA GLUTAMYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALLERGIC REACTION; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CHILD PUGH SCORE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; FEVER; FOLLOW UP; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LABORATORY TEST; LAENNEC FIBROSIS SCORING SYSTEM; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MARROW-DERIVED MESENCHYMAL STEM CELL; CIRRHOSIS; HEPATIC FIBROSIS; LIVER FUNCTION; PORTAL HYPERTENSION;

ACTINS; ADULT; BIOPSY; CELLS, CULTURED; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRA-ARTERIAL; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84890127523     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12218     Document Type: Article

References (33)

1. Bolondi L, Gramantieri L. From liver cirrhosis to HCC. Intern Emerg Med 2011; 6(Suppl. 1): 93-8.
2. Iredale JP. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 2003; 327: 143-7.
3. Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol 2009; 21: 1241-6.
4. Kim MY, Suk KT, Baik SK, et al. Hepatic vein arrival time as assessed by contrast-enhanced ultrasonography is useful for the assessment of portal hypertension in compensated cirrhosis. Hepatology 2012; 56: 1053-62.
5. Lee SS, Shin HS, Kim HJ, et al. Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. Korean J Hepatol 2012; 18: 48-55.
6. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 1572-85.
7. Kim MY, Cho MY, Baik SK, et al. Beneficial effects of candesartan, an angiotensin-blocking agent, on compensated alcoholic liver fibrosis - A randomized open-label controlled study. Liver Int 2012; 32: 977-87.
8. Kwon OS, Jung YK, Kim YS, et al. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol 2010; 16: 308-14.
9. Singal AK, Duchini A. Liver transplantation in acute alcoholic hepatitis: current status and future development. World J Hepatol 2011; 3: 215-8.
10. Strom SC, Bruzzone P, Cai H, et al. Hepatocyte transplantation: clinical experience and potential for future use. Cell Transplant 2006; 15(Suppl. 1): S105-10.
11. Strom S, Fisher R. Hepatocyte transplantation: new possibilities for therapy. Gastroenterology 2003; 124: 568-71.
12. Kakinuma S, Nakauchi H, Watanabe M. Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. J Gastroenterol 2009; 44: 167-72.
13. Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol 2009; 21: 1199-205.
14. Cho KA, Lim GW, Joo SY, et al. Transplantation of bone marrow cells reduces CCl4 -induced liver fibrosis in mice. Liver Int 2011; 31: 932-9.
15. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40: 1304-11.
16. Hardjo M, Miyazaki M, Sakaguchi M, et al. Suppression of carbon tetrachloride-induced liver fibrosis by transplantation of a clonal mesenchymal stem cell line derived from rat bone marrow. Cell Transplant 2009; 18: 89-99.
17. Higashiyama R, Inagaki Y, Hong YY, et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007; 45: 213-22.
18. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 2011; 193: 225-31.
19. Pai M, Zacharoulis D, Milicevic MN, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol 2008; 103: 1952-8.
20. Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 2008; 12: 939-62.
21. Sakaida I, Terai S, Nishina H, Okita K. Development of cell therapy using autologous bone marrow cells for liver cirrhosis. Med Mol Morphol 2005; 38: 197-202.
22. Terai S, Ishikawa T, Omori K, et al. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006; 24: 2292-8.
23. Am Esch JS 2nd, Knoefel WT, Klein M, et al. Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration. Stem Cells 2005; 23: 463-70.
24. van Poll D, Parekkadan B, Cho CH, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008; 47: 1634-43.
25. D'amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
26. Veldt BJ, Laine F, Guillygomarc'h A, et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 2002; 36: 93-8.
27. Hu Y, Liao L, Wang Q, et al. Isolation and identification of mesenchymal stem cells from human fetal pancreas. J Lab Clin Med 2003; 141: 342-9.
28. Martin JY, Dean DD, Cochran DL, et al. Proliferation, differentiation, and protein synthesis of human osteoblast-like cells (MG63) cultured on previously used titanium surfaces. Clin Oral Implant Res 1996; 7: 27-37.
29. Kim MY, Cho MY, Baik SK, et al. Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011; 55: 1004-9.
30. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566-9.
31. Calvaruso V, Burroughs AK, Standish R, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009; 49: 1236-44.
32. Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol 2012; 18: 1-21.
33. Peng L, Xie DY, Lin BL, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology 2011; 54: 820-8.